Detail of "143011-72-7"

Reference

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo. Aman, M. J.; Stockdreher, K.; Thews, A.; Kienast, K.; Aulitzky, W. E.; Faerber, L.; Haus, U.; Koci, B.; Huber, C.; Peschel, C. (School Medicine, Johannes Gutenberg University, Mainz D-55131, Germany). Annals of Hematology, 73(5), 231-238 (English) 1996 Springer.Several substances with their cas registry numbers 143011-72-7 and 83869-56-1 may be metioned in this study. CODEN: ANHEE8. ISSN: 0939-5555. DOCUMENT TYPE: Journal CA Section: 15 (Immunochemistry) Section cross-reference(s): 14 The influence on the activation of cytokine synthesis and on the expression of surface antigens with cellular activation of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in cancer patients receiving these factors. One single dose of growth factor was administered to patients with bladder cancer (G-CSF group) or small lung cancer (GM-CSF group). After cytoreductive chemotherapy patients received supportive therapy with G-CSF or GM-CSF. Among mature hematopoietic cells G-CSF influenced the granulocyte lineage, GM-CSF caused moderate modulation of monocyte function. The expression of MHC class-II mols. and CD44 was stimulated on peripheral blood monocytes. The plasma levels of sCD25 and IL-1RA increased. The mRNA expression for IL-8 and IL-1RA was unchanged. Apparently, immunomodulatory features were regulated differentially by G-CSF and GM-CSF. .

Control of norleucine incorporation into recombinant proteins

Control of norleucine incorporation into recombinant proteins. Fenton, Dennis; Lai, Por-hsiung; Lu, Hsieng; Mann, Michael; Tsai, Larry (Amgen Inc., USA). U.S. US 5599690 A 4 Feb 1997, 11 pp., Cont. of U.S. Ser. No. 880, 462, abandoned. (English). 143011-72-7 and 61-90-5 which are cas registry numbers are also used here. (United States of America). CODEN: USXXAM. CLASS: ICM: C12P021-02. ICS: C12P021-04. NCL: 435069100. APPLICATION: US 1994-363862 22 Dec 1994. PRIORITY: US 1988-151170 1 Feb 1988; US 1992-880462 5 May 1992. DOCUMENT TYPE: Patent CA Section: 16 (Fermentation and Bioindustrial Chemistry) Norleucine incorporation into recombinant gene products may be inhibited by culturing the cells expressing the gene products in media comprising a high level of leucine and/or methionine, or by expressing the gene products in a leu mutant. Norleucine incorporation in recombinant gene products may be promoted by culturing the cells expressing the gene products in media comprising norleucine or deficient in leucine and/or methionine. For example, norleucine analogs of IL-2, GCSF, g-interferon and a-consensus interferon may be produced in this way. .